.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Deloitte
Mallinckrodt
Medtronic
Queensland Health
UBS
Novartis
AstraZeneca
Johnson and Johnson
Teva

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,501,698

« Back to Dashboard

Which drugs does patent 8,501,698 protect, and when does it expire?


Patent 8,501,698 protects BYDUREON PEN, XIGDUO XR, FARXIGA, and QTERN, and is included in four NDAs.

This patent has sixty patent family members in thirty-one countries.

Summary for Patent: 8,501,698

Title:Crystal structures of SGLT2 inhibitors and processes for preparing same
Abstract: The present invention relates to physical crystal structures of a compound of the formula I: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.2a, R.sup.3 and R.sup.4 are as defined herein, especially ##STR00002## pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
Inventor(s): Gougoutas; Jack Z. (Princeton, NJ), Lobinger; Hildegard (Princeton, NJ), Ramakrishnan; Srividya (Princeton, NJ), Deshpande; Prashant P. (Princeton, NJ), Bien; Jeffrey T. (Princeton, NJ), Lai; Chiajen (Princeton, NJ), Wang; Chenchi (Princeton, NJ), Riebel; Peter (Princeton, NJ), Grosso; John Anthony (Princeton, NJ), Nirschl; Alexandra A. (Princeton, NJ), Singh; Janak (Princeton, NJ), DiMarco; John D. (Princeton, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:13/049,712
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca AbBYDUREON PENexenatide syntheticFOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS022200-002Feb 28, 2014RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-005Jul 28, 2017RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-002Oct 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-001Oct 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-004Oct 29, 2014RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbXIGDUO XRdapagliflozin propanediol; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL205649-003Oct 29, 2014RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-001Jan 8, 2014RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbFARXIGAdapagliflozin propanediolTABLET;ORAL202293-002Jan 8, 2014RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca AbQTERNdapagliflozin propanediol; saxagliptin hydrochlorideTABLET;ORAL209091-001Feb 27, 2017RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,501,698

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,919,598Crystal structures of SGLT2 inhibitors and processes for preparing same► Subscribe
9,453,039Crystal structures of SGLT2 inhibitors and processes for preparing same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,501,698

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan5666651► Subscribe
Japan2013209394► Subscribe
Japan5313889► Subscribe
Japan2009545525► Subscribe
Israel245688► Subscribe
Israel214180► Subscribe
Israel214181► Subscribe
Israel214182► Subscribe
European Patent Office3045466► Subscribe
European Patent Office2069374► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
AstraZeneca
Boehringer Ingelheim
Chinese Patent Office
Baxter
Fuji
Accenture
Farmers Insurance
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot